iCAD,
Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image
analysis, workflow solutions and radiation therapy for the early
identification and treatment of cancer, today announced a strategic
alliance with DermEbx™ to offer the Xoft® Axxent®
Electronic Brachytherapy System® to treat non-melanoma skin
cancer (NMSC) throughout the DermEbx network of dermatology centers.
DermEbx currently services 14 locations in Arizona, California and
Nevada with Xoft System units placed in all locations.
“We are pleased to provide patients diagnosed with non-melanoma skin
cancer this innovative and effective treatment option that is
administered in their dermatologist’s office under the supervision of a
radiation oncologist,” said Ken Ferry, iCAD’s CEO. “Electronic
brachytherapy is a proven, non-invasive alternative to surgery, and this
strategic alliance will allow us to expand the number of systems we have
in place to treat more patients at centers managed by DermEbx. This
agreement provides patients with a proven, convenient treatment
alternative in a familiar care environment.”
“We are excited to bring the Xoft System to our managed centers as part
of this strategic alliance,” said Kamal Gogineni, President of DermEbx.
“The collaboration between DermEbx, dermatologists and its affiliated
radiation oncologists will help create a comprehensive solution for this
advanced technology in treating skin cancer patients.”
“DermEbx integrates the mobile Xoft System into its dermatology centers
by allowing treatment to occur in the facility where the diagnosis is
made, potentially eliminating the need to visit multiple service
providers at different locations,” said David Berman, M.D., Medical
Director, Berman Gladstone Skin Institute. “The mobility of the Xoft
System enables a radiation oncologist to treat more patients at multiple
dermatology centers.”
About Non-Melanoma Skin Cancer
NMSC, identified as either basal cell carcinoma or squamous cell
carcinoma, is not only the most common type of skin cancer, it is the
most common type of cancer in humans. These cancers commonly appear on
sun-exposed areas of the body such as the face, ears, neck, lips and
backs of the hands. NMSC affects approximately 2.2 million Americans
each year.
About Xoft Axxent Electronic Brachytherapy
System
The Xoft System is an isotope-free radiation treatment cleared by the
U.S. Food and Drug Administration and CE marked in the EU for use
anywhere in the body, including for the treatment of early stage breast
cancer, endometrial cancer, cervical cancer and skin cancer. It utilizes
a proprietary miniaturized x-ray as the radiation source that delivers
precise treatment directly to cancerous areas while sparing healthy
tissue and organs. Xoft is a wholly owned subsidiary of iCAD, Inc. For
more information about Xoft visit www.xoftinc.com.
About DermEbx
Founded in January 2013, DermEbx is a leading healthcare services and
technology company dedicated to offering skin electronic brachytherapy
programs to Dermatology and Oncology Networks. This program includes
collaboration with clinical care teams and management staff in
successfully integrating equipment and software into a patient-centric
workflow model. DermEbx helps its customers with scalability and
operational efficiencies in delivering programs that meet quality and
standards for improved patient care. For more information, call
408-625-7710 or visit www.dermEbx.com.
About iCAD, Inc.
iCAD is a leading provider of advanced image analysis, workflow
solutions and radiation therapies for the early identification and
treatment of common cancers. iCAD offers a comprehensive range of
high-performance, upgradeable CAD solutions for mammography and advanced
image analysis and workflow solutions for Magnetic Resonance Imaging,
for breast and prostate cancers and Computed Tomography for colorectal
cancer. iCAD’s Xoft System, offers radiation treatment for early-stage
breast cancer that can be administered in the form of intraoperative
radiation therapy or accelerated partial breast irradiation. The Xoft
System is also cleared for the treatment of non-melanoma skin cancer,
cervical cancer and endometrial cancer. For more information, call
877-iCADnow, or visit www.icadmed.com.
"Safe Harbor" Statement under the Private Securities Litigation
Reform Act of 1995:
Certain statements contained in this News Release constitute
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. Such forward-looking
statements involve a number of known and unknown risks, uncertainties
and other factors which may cause the actual results, performance or
achievements of the Company to be materially different from any future
results, performance or achievements expressed or implied by such
forward-looking statements. Such factors include, but are not limited
to, the Company’s ability to defend itself in litigation matters, the
Company’s ability to identify a replacement for the Axxent FlexiShield
Mini, the risks relating to the Company’s acquisition of Xoft including,
the expected benefits of the acquisition may not be achieved in a timely
manner, or at all; the Xoft business operations may not be successfully
integrated with iCAD’s and iCAD may be unable to achieve the expected
synergies, business and strategic objectives following the transaction,
the risks of uncertainty of patent protection; the impact of supply and
manufacturing constraints or difficulties; product market acceptance;
possible technological obsolescence; increased competition; customer
concentration; and other risks detailed in the Company’s filings with
the Securities and Exchange Commission. The words “believe”,
“demonstrate”, “intend”, “expect”, “estimate”, “anticipate”, “likely”,
and similar expressions identify forward-looking statements. Readers are
cautioned not to place undue reliance on those forward-looking
statements, which speak only as of the date the statement was made. The
Company is under no obligation to provide any updates to any information
contained in this release. For additional disclosure regarding
these and other risks faced by iCAD, please see the disclosure contained
in our public filings with the Securities and Exchange Commission,
available on the Investors section of our website at http://www.icadmed.com
and on the SEC’s website at http://www.sec.gov.
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20130911006300/en/
Copyright Business Wire 2013